<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Alnylam Pharmaceuticals Inc. | Company News & Executive Profiles - ALNY | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Alnylam Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="54" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Alnylam Wins Another China Patent for siRNA]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F134258-alnylam-wins-another-china-patent-for-sirna%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Alnylam Pharmaceuticals (NSDQ: ALNY) was granted a China patent on a crucial short interfering RNAs siRNAs patent, the Tuschl II series. This patent includes 44 claims covering compositions, methods, uses, and systems for siRNAs, the molecules that mediate RNAi. Previously, Alnylam was awarded a patent for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 30 Apr 2009 05:01:21 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="tickers">ALNY</category>
	</item>
	<item>
		<title><![CDATA[Alnylam Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-272712.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator (Operator's instruction) Your first question comes from the line of Sapna Srivastava - Morgan Stanley. Analyst for Sapna Srivastava - Morgan Stanley It is Dave calling in for Sapna. Just a question on delivery, I know that is sort of an ongoing topic for everyone in the...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 24 Feb 2009 20:57:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[Formulation]]></category>
		<category domain="http://resources.bnet.com/topic/delivery.html"><![CDATA[Delivery]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/cell.html"><![CDATA[Cell]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="tickers">ALNY</category>
	</item>
	<item>
		<title><![CDATA[Cubist and Alnylam, An Odd Partnership]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F114245-cubist-and-alnylam-an-odd-partnership%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:  Cubist CBST and Alnylam ALNY have formed a strategic collaboration to develop and commercialize Alnylam&#8217;s ALN-RSV program. The RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Sun, 11 Jan 2009 09:57:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cubist+pharmaceuticals+inc..html"><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CBST</category>
		<category domain="tickers">ALNY,CBST</category>
	</item>
	<item>
		<title><![CDATA[Can MicroRNA Reverse Heart Disease?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F108559-can-microrna-reverse-heart-disease%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: Regulus Therapeutics, a joint venture between Alnylam ALNY and Isis ISIS formed to discover, develop, and commercialize microRNA-based therapeutics, announced the publication of new research in the journal Nature on the role of a microRNA, known as miR-21, in heart failure.  Apparently, this is the first...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 01 Dec 2008 07:57:30 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ALNY,ISIS</category>
	</item>
	<item>
		<title><![CDATA[Alnylam Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-250145.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you. Operator instructions Your first question comes from the line of Sapna Srivastava with Morgan Stanley. Please proceed. Dave &#8211; Morgan Stanley  Hi, thanks. It&#8217;s Dave [ph] calling in for Sapna. John Maraganore  Hi, Dave, how are you? Dave &#8211; Morgan Stanley ...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 18 Nov 2008 01:21:10 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/europe.html"><![CDATA[Europe]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/morgan+stanley.html"><![CDATA[Morgan Stanley]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/dave.html"><![CDATA[Dave]]></category>
		<category domain="http://resources.bnet.com/topic/david+glover.html"><![CDATA[David Glover]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/europe.html"><![CDATA[Europe]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/morgan+stanley.html"><![CDATA[Morgan Stanley]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/dave.html"><![CDATA[Dave]]></category>
		<category domain="http://resources.bnet.com/topic/david+glover.html"><![CDATA[David Glover]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MS</category>
		<category domain="tickers">ALNY,MS</category>
	</item>
	<item>
		<title><![CDATA[Alnylam and RNAi: The Truth Hurts]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F92005-alnylam-and-rnai-the-truth-hurts%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Many readers will well remember when Merck MRK bought the RNA-interference company Sirna in 2006. They paid over a billion dollars for them, and made the whole RNA area an even bigger field for speculation than it was already. Another big player in that field is...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 21 Aug 2008 08:08:54 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="tickers">ALNY</category>
	</item>
	<item>
		<title><![CDATA[Alnylam Pharmaceuticals: A Falling Star]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F91936-alnylam-pharmaceuticals-a-falling-star%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Huckman submits:  Until the bearish call yesterday morning, shares of Alnylam ALNY were trading around $33 a share. But Leerink Swann, which specializes in biopharma/healthcare equities research, initiated coverage of the stock yesterday with an "Underperform" rating saying it should soon be worth less than half its value...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 21 Aug 2008 02:12:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="tickers">ALNY</category>
	</item>
	<item>
		<title><![CDATA[Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_19/ai_n28010733]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in the journal Molecular and Cellular Biology on the role of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 19 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/cell.html"><![CDATA[cell]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/rna.html"><![CDATA[RNA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">ALNY,ISIS,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[My Model Biotech Picks: What's Hot and What's Not]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F90661-my-model-biotech-picks-what-s-hot-and-what-s-not%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[A. Reza Saadat submits:  Analyzing the performance of my previous picks is by far my favorite part of writing this blog. It has on many occasions allowed be to learn from my mistakes.I have moved the numbers to Google docs so that they are easier to read. Here is...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 13 Aug 2008 12:36:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/amylin+pharmaceuticals+inc..html"><![CDATA[Amylin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/rigel+pharmaceuticals+inc..html"><![CDATA[Rigel Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/seattle+genetics+inc..html"><![CDATA[Seattle Genetics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMLN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RIGL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
		<category domain="tickers">ALNY,AMGN,AMLN,CELG,RIGL,SGEN</category>
	</item>
	<item>
		<title><![CDATA[Alnylam Awarded Continued Funding Under U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_6/ai_n27971532]]></link>
		<description><![CDATA[Commitment for Continued Funding of $7.5 Million Supports Alnylam Biodefense[TM] Efforts and Broad Technology Development  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that the National Institute of Allergy and Infectious Diseases NIAID, a component of the National Institutes of Health NIH,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 06 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alnylam+pharmaceuticals+inc..html"><![CDATA[Alnylam Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/bioterrorism.html"><![CDATA[bioterrorism]]></category>
		<category domain="http://resources.bnet.com/topic/infection.html"><![CDATA[infection]]></category>
		<category domain="http://resources.bnet.com/topic/rna.html"><![CDATA[RNA]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+government.html"><![CDATA[U.S. Government]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
		<category domain="tickers">ALNY</category>
	</item>
</channel>
</rss>
